It doesn't require a great deal of skepticism to question the significance of differences of a few percentage points in absolute risk reduction of composite end points in ASCVD trials. The same statement can be applied to statin therapy or any other manipulation of lipoprotein levels, anti-inflammatory meds, or any other "risk factor". T…
It doesn't require a great deal of skepticism to question the significance of differences of a few percentage points in absolute risk reduction of composite end points in ASCVD trials. The same statement can be applied to statin therapy or any other manipulation of lipoprotein levels, anti-inflammatory meds, or any other "risk factor". The blind alley that is the risk factor paradigm for ASCVD has gotten us nowhere over the past 70 years.
It doesn't require a great deal of skepticism to question the significance of differences of a few percentage points in absolute risk reduction of composite end points in ASCVD trials. The same statement can be applied to statin therapy or any other manipulation of lipoprotein levels, anti-inflammatory meds, or any other "risk factor". The blind alley that is the risk factor paradigm for ASCVD has gotten us nowhere over the past 70 years.